Reports

Drug name	NICE TAs	Comments
Clopidogrel 75mg tablets	TA80 - Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colistimethate sodium	TA276 - Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis	Amber: Existing patients (initiated prior to April 2013) Promixin® - Powder for nebuliser solution Colomycin® Injection may be used for nebulisation; administer required dose in 2-4 mL of sodium chloride 0.9%, (or water for injections) or a 1:1 mixture of sodium chloride 0.9% and water for injection Colobreathe® - Dry powder for inhalation, hard capsule (NICE TA276)
Colistimethate sodium#3.7	TA276 - Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis	NHS England commissioned for cystic fibrosis only. Red for new patients.
Crizanlizumab (Adakveo®)	TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease
Crizotinib	TA296 - Critzotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene TA529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Cytarabine–daunorubicin liposomal (Vyxeos®)	TA552 - Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Dabigatran capsules	TA249 - Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation TA327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	Following diagnosis of AF – use in line NICE and toolkit, initiation/recommendation by haematologist, transfer to GP with RICaD. For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/recommendation by haematologist, transfer to GP with RICaD Adults only
Dabrafenib	TA321 - Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib with trametinib	TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
Daclizumab concentrate for infusion	TA441 - Daclizumab for treating relapsing–remitting multiple sclerosis	For Hospital Use Only. Please see drug safety alert. Safety alert

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports